Q3 2024 TG Therapeutics Inc Earnings Call Transcript
Key Points
- TG Therapeutics Inc (TGTX) reported strong third-quarter US net sales of $83.3 million, reflecting approximately 15% quarter-over-quarter growth and over 230% growth from the same quarter last year.
- The company has achieved significant market penetration with BRIUMVI, reaching nearly 1,100 prescribers across approximately 600 centers, including 95% of the top 100 MS centers.
- Positive long-term data from the ultimate one and two trials showed that 92% of patients were free from disability progression after five years of BRIUMVI treatment.
- TG Therapeutics Inc (TGTX) is expanding its commercial infrastructure, having nearly doubled its commercial field team over the last two years to support rising demand.
- The company is exploring new market opportunities with the development of a subcutaneous version of BRIUMVI, which could open up a new market segment for at-home self-administration.
- The company faces risks associated with forward-looking statements, which may cause actual results to differ materially from expectations.
- TG Therapeutics Inc (TGTX) is moving away from providing specific enrollment numbers due to fluctuating capture rates, particularly as more hospitals, which are less likely to use the company's hub, become involved.
- The timeline for incorporating faster infusion times and skipping loading doses into clinical practice could take 2 to 3 years, indicating a lengthy process for label updates.
- The company has not yet provided specific shares for newly diagnosed or new to CD 20 patients, which may limit visibility into market penetration in these segments.
- There is uncertainty regarding the pace of enrollment and data availability for the phase one study of Azure cell, an investigational CD 19 CAR T cell therapy, which may impact timelines for potential new treatments.
Greetings and welcome to the TG Therapeutics third quarter conference call and webcast. At this time, all participants are in listen-only mode.
If anyone should require operator assistance, please press star zero on your telephone keypad.
A question-and-answer session will follow the formal presentation. You may be placed in the question queue at any time by pressing star one on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Jenna Bosco. Please go ahead.
Thank you, welcome everyone and thanks for joining us this morning. I'm Jenna Bosco and with me today to discuss the third quarter, 2024 financial results are Michael Weiss, our Chairman and Chief Executive Officer, Adam Waldman, our Chief Commercialization Officer and Sean Power, our Chief Financial Officer following our safe harbor statement. Mike will provide an overview of our recent corporate developments.
Adam will share an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
